Phase I/II Clinical Trial of the Combination of Trastuzumab (Herceptin) and 17-allylamino-17-demethoxy-geldanamycin (KOS-953; 17-aag)

Trial Profile

Phase I/II Clinical Trial of the Combination of Trastuzumab (Herceptin) and 17-allylamino-17-demethoxy-geldanamycin (KOS-953; 17-aag)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2008

At a glance

  • Drugs Tanespimycin; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Kosan Biosciences
  • Most Recent Events

    • 14 May 2008 Updated results will be presented at the American Society of Clinical Oncolgy 2008 meeting, according to a Kosan media release.
    • 16 Dec 2007 Preliminary results from 20 clinically evaluable patients were presented at the 2007 San Antonio Breast Cancer Symposium held in San Antonio, Texas, USA.
    • 22 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top